|
Total
|
474
|
394
|
83.1%
|
80
|
16.9%
|
(13.6%, 20.6%)
|
|
Sex—no. (%)
| | | | | | | |
|
Male
|
182
|
38.4%
|
156
|
85.7%
|
26
|
14.3%
|
(9.6%, 20.2%)
|
|
Female
|
292
|
61.6%
|
238
|
81.5%
|
54
|
18.5%
|
(14.2%, 23.4%)
|
|
Age—mean (Std)
|
42.0
|
11.30
|
41.9
|
11.3
|
42.4
|
11.5
|
N/A
|
|
Race—no. (%)
| | | | | | | |
|
Non-Hispanic White
|
339
|
71.5%
|
286
|
84.4%
|
53
|
15.6%
|
(11.9%, 20.0%)
|
|
Hispanic or Latino
|
31
|
6.5%
|
24
|
77.4%
|
7
|
22.6%
|
(9.6%, 41.1%)
|
|
African American/Black
|
14
|
3.0%
|
13
|
92.9%
|
1
|
7.1%
|
(0.2%, 33.9%)
|
|
Asian
|
87
|
18.4%
|
68
|
78.2%
|
19
|
21.8%
|
(13.7%, 32.0%)
|
|
Others/unknown
|
3
|
0.6%
|
3
|
100.0%
|
0
|
0.0%
|
N/A
|
|
Had a PCR test—no. (%)
|
65
|
13.7%
|
48
|
73.8%
|
17
|
26.2%
|
(16.0%, 38.5%)
|
|
# Days from first PCR test to antibody test (must have occurred before the antibody test)—median, IQR
|
15
|
[11, 22]
|
14
|
[9, 20]
|
17
|
[13.0, 24.0]
|
N/A
|
|
Symptom groups—no. (%)
| | | | | | | |
|
Asymptomatic since 15 February 2020
|
244
|
51.5%
|
214
|
87.7%
|
30
|
12.3%
|
(8.5%, 17.2%)
|
|
Symptomatic, but no +PCR test prior to our AB samples
|
217
|
45.8%
|
178
|
82.0%
|
39
|
18.0%
|
(13.1%, 23.7%)
|
|
PCR+ test prior to our AB samples
|
13
|
2.7%
|
2
|
15.4%
|
11
|
84.6%
|
(54.6%, 98.1%)
|
|
# Days from symptom onset to first Ab test (n = 230) —median (IQR)
|
25.5
|
[17.0, 38.0]
|
24
|
[15.5, 39.0]
|
29.5
|
[21.0, 38.0]
|
N/A
|
